Despite disagreeing with accusations that it fails to comply with regulatory practices, Akorn is something of a full employment act for Food and Drug Administration inspectors.

The agency released another in an ongoing stream of inspection reports that have found quality control problems at different Akorn plants in the U.S. and elsewhere. The concerns included a failure to review unexplained discrepancies in batches and consistently investigate issues with batch samples; procedures for quality control were not in writing; and a failure to validate procedures to avoid contamination.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy